Volume 30, Number 11—November 2024
Synopsis
Mortality Rates after Tuberculosis Treatment, Georgia, USA, 2008–2019
Sarah Gorvetzian1, Antonio G. Pacheco, Erin Anderson, Susan M. Ray, and Marcos C. Schechter
Table 4
Comparisons of causes of death between patients who finished TB treatment and the general population in study of mortality rates after TB treatment, Georgia, USA, 2008–2019*
| Categories | No. (%) persons |
Odds ratio (95% CI)† | Age at death, y, mean (SD) | |
|---|---|---|---|---|
| Posttreatment deaths | Georgia population deaths | |||
| Total no. persons | 233 | 900,874 | NA | 233 |
| Cardiovascular disease | 56 (24.0) | 271,146 (30.1) | 0.73 (0.54–0.99) | 67.8 (14.8) |
| HIV | 22 (9.9) | 4,789 (0.5) | 19.6 (12.6–30.4) | 49.6 (11.3) |
| Malignancy | 56 (24.0)‡ | 193,983 (21.5) | 1.15 (0.85–1.55) | 64.5 (12.0) |
| Pulmonary disease | 26 (11.2)§ | 90,880 (10.1) | 1.11 (0.74–1.68) | 68.7 (14.9) |
| Trauma/poisoning | 16 (6.9) | 68,550 (7.6) | 0.89 (0.53–1.48) | 63.3 (14.3) |
| Other | 57 (24.5) | 271,526 (30.1) | 0.75 (0.55–1.01) | 68.0 (14.2) |
*NA, not applicable; TB, tuberculosis. †Odds of dying in posttreatment group compared with the general Georgia population. ‡Pulmonary malignancy, n = 21 (37.5% of total malignancies, 9% of total deaths). §Pulmonary TB/mycobacterial infection, n = 7.
1Current affiliation: University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Page created: September 12, 2024
Page updated: October 22, 2024
Page reviewed: October 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Content Credential